

Article

PPAR- γ Agonist GW1929 Targeted to Macrophages with Dendrimer–Graphene Nanostars Reduces Liver Fibrosis and Inflammation

Alazne Moreno-Lanceta ^{1,2}, Mireia Medrano-Bosch ¹, Blanca Simón-Codina ¹, Montserrat Barber-González ¹, Wladimiro Jiménez ^{1,2} and Pedro Melgar-Lesmes ^{1,2,3,*}

¹ Department of Biomedicine, School of Medicine, University of Barcelona, 08036 Barcelona, Spain; amorenol@recerca.clinic.cat (A.M.-L.)

² Biochemistry and Molecular Genetics Service, Hospital Clínic Universitari, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), 08036 Barcelona, Spain

³ Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA

* Correspondence: pmelgar@ub.edu; Tel.: +34-934020294

Table S1. Serum parameters of liver damage (alanine aminotransferase (ALT) and aspartate aminotransferase (AST)) and liver function (albumin and total protein) in fibrotic mice treated with dendrimer-graphene nanostars linked to mannitol (DGNS-Man) or GW1929 (DGNS-GW).

Serum parameter	DGNS-Man (N=6)	DGNS-GW (N=6)
ALT (U/L)	37.13 \pm 9.12	40.46 \pm 5.46
AST (U/L)	277.8 \pm 155	332.4 \pm 66.87
Albumin (g/L)	27.05 \pm 0.22	27.19 \pm 0.37
Total protein (g/L)	49.53 \pm 0.77	47.65 \pm 0.89




Figure S1. Immunofluorescent staining of pro-inflammatory M1-like markers (NOS2 and COX-2) and anti-inflammatory M2-like markers (MRC1 and ARG1) in the liver of in fibrotic mice treated with dendrimer-graphene nanostars linked to mannitol (DGNS-Man) or GW1929 (DGNS-GW). Scale bar: 250 μ m.